Methamphetamine-associated dysregulation of the hypothalamic-pituitary-thyroid axis

Area of Science:

• Endocrinology
• Infectious Diseases
• Public Health

Background:

• Methamphetamine (METH) and human immunodeficiency virus (HIV) are known to independently affect thyroid function.
• Limited research exists on the combined impact of METH use and HIV infection on thyroid dysregulation, particularly within specific populations.

Purpose of the Study:

• To investigate the associations between methamphetamine use, HIV status, and thyroid function among men who have sex with men (MSM).
• To compare thyroid function measures across groups: METH-using and HIV-infected (METH+HIV+), METH-using and HIV-negative (METH+HIV-), and non-METH-using and HIV-negative (METH-HIV-).

Main Methods:

• Cross-sectional study comparing thyroid function markers (thyroid stimulating hormone, free triiodothyronine) in three groups of MSM.
• Statistical analysis to determine odds of abnormal thyroid function and mean differences in hormone levels.

Main Results:

• Thyroid function was dysregulated in methamphetamine-using MSM, irrespective of HIV status.
• METH-using groups (both METH+HIV+ and METH+HIV-) showed higher odds of abnormal thyroid stimulating hormone levels.
• Significantly higher mean free triiodothyronine (T3) levels were observed in METH-using MSM compared to controls.
• Elevated free T3 levels were associated with increased depressive symptoms.

Conclusions:

• Methamphetamine use is linked to thyroid dysregulation in MSM, independent of HIV status.
• Findings highlight the need for thyroid function assessment in methamphetamine users, especially those with depression.
• These results have implications for clinical management and public health strategies concerning substance use and chronic infections.